# Bliss GVS Pharma share price today (Bliss GVS Pharma Ltd, NSE: BLISSGVS) > Bliss GVS Pharma share price today: ₹680.35 at the NSE close on 18 November 2026, up 325.8% in a year. Bliss GVS Pharma (NSE: BLISSGVS) is worth ₹7,239 crore, trades at a P/E of 44.8 and has closed between ₹144.37 and ₹739.90 over the past 52 weeks. > Bliss GVS Pharma Ltd's share price has risen faster than its earnings: +325.8% in a year, against +52.6% for earnings per share. BLISSGVS · Pharma - Formulators · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Mixed, from fewer quarters than usual - Price: ₹680.35 (+325.8% in a year) - P/E: 44.8× (higher than 98% of the last 11 years) - Revenue (Sep 2026): ₹313 Cr (+28.3% on a year ago) - Profit (Sep 2026): ₹53.0 Cr (+82.8% on a year ago) - Operating margin: 25.9% (+8.3 points on a year ago) - ROCE: 17%, FY26 - Profit that came in as cash: 113%, last 3 years The main question: the share price moved +325.8% in a year while yearly earnings per share moved +52.6%. The difference came from the market paying a higher multiple. ## What is the Bliss GVS Pharma share price today? Bliss GVS Pharma Ltd's share price was ₹680.35 at the close on 18 November 2026. It has been rising for 72 weeks. That is 43.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹144 and ₹740, and at that close it sat 90% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. Over the last 11 years the share price moved +342% while the NIFTY 500 moved +306%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 13 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Bliss GVS Pharma this quarter? 1 points in one quarter, foreign funds (FIIs) cut their stake for 3 quarters in a row and highest quarterly profit in 17 quarters. 1. Promoters raised their stake by 15.1 points in one quarter From 35% to 50.1% in the September 2026 quarter. 2. Foreign funds (FIIs) cut their stake for 3 quarters in a row From 14.5% to 5% of the company by the September 2026 quarter. 3. Highest quarterly profit in 17 quarters Profit of ₹53 crore in the September 2026 quarter is the highest of the last 17 quarters. ## What are Bliss GVS Pharma's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Bliss GVS Pharma reported revenue of ₹313 crore, up 28.3% from ₹244 crore a year earlier, and a profit of ₹53.0 crore, up 82.8% from ₹29.0 crore. ### Bliss GVS Pharma results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹313 crore | ₹244 crore | +28.3% | | Profit | ₹53.0 crore | ₹29.0 crore | +82.8% | | Earnings per share | ₹4.91 | ₹2.58 | +90.3% | | Operating margin | 25.9% | 17.6% | +8.3 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Bliss GVS Pharma share price history? Bliss GVS Pharma closed at ₹680.35 on 18 November 2026, up 325.8% from ₹159.79 a year earlier (21 November 2025) and up 573.9% over five years. Its highest weekly close since February 2016 was ₹739.90 on 28 September 2026. ### Bliss GVS Pharma share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹656.30 | +3.7% | | 1 month ago · 19 Oct 2026 | ₹627.05 | +8.5% | | 6 months ago · 15 May 2026 | ₹277.65 | +145.0% | | 1 year ago · 21 Nov 2025 | ₹159.79 | +325.8% | | 3 years ago · 17 Nov 2023 | ₹129.85 | +424.0% | | 5 years ago · 18 Nov 2021 | ₹100.95 | +573.9% | | 10 years ago · 18 Nov 2016 | ₹128.90 | +427.8% | | Earliest weekly close in our records · 26 Feb 2016 | ₹154.00 | +341.8% | | Highest weekly close since February 2016, also the 52-week high · 28 Sep 2026 | ₹739.90 | −8.0% | | Lowest weekly close since February 2016 · 13 May 2022 | ₹68.40 | +894.7% | | 52-week low (weekly close) · 12 Dec 2025 | ₹144.37 | +371.3% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (569 weekly closes from 26 February 2016 to 18 November 2026.) ## What is the latest news on Bliss GVS Pharma? 18 Nov 2026: Bliss GVS Pharma closed at ₹680.35, up 3.7% on the week and up 8.5% on the month. Results for July to September 2026: Revenue up 28.3% and profit up 82.8% on a year earlier. ### Earlier - 8 Jul 2026: ex-date for a dividend of ₹1 a share. - 18 Feb 2026: ex-date for an interim dividend of ₹0.50 a share. ## What dividend does Bliss GVS Pharma pay? Bliss GVS Pharma paid ₹1.50 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 0.22% at the ₹680.35 close on 18 November 2026. The last was a dividend of ₹1 a share, ex-date 8 July 2026. ### Bliss GVS Pharma dividends since 1 April 2021 | Ex-date | Dividend per share | Type | | --- | --- | --- | | 8 Jul 2026 | ₹1 | Dividend | | 18 Feb 2026 | ₹0.50 | Interim | | 24 Jul 2025 | ₹0.50 | Dividend | | 18 Jul 2024 | ₹0.50 | Dividend | | 12 Jul 2023 | ₹0.50 | Dividend | | 20 Jun 2022 | ₹0.50 | Dividend | | 13 Sep 2021 | ₹0.50 | Dividend | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Bliss GVS Pharma Ltd paid out 4% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 18 November 2026.) ## What to watch in Bliss GVS Pharma's next results? When Bliss GVS Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was +28.3% on a year earlier, and the last four quarters averaged +25.0%. - Whether the operating margin stays near 25.9%. It is 8.3 percentage points higher than four quarters earlier. - Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +82.8% on a year earlier. It has grown on a year earlier for 3 quarters in a row. ## Which stock lists is Bliss GVS Pharma on? Bliss GVS Pharma is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market value: ₹6,983 crore](https://www.sectoralpha.in/momentum-stocks-india) - [Pharma stocks Market value: ₹6,983 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Bliss GVS Pharma profitable? Bliss GVS Pharma Ltd earned ₹53.0 Cr of net profit in the Sep 2026 quarter, +82.8% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹135 Cr. Over 10 years profit has grown 3.0% a year on average. The same quarter a year earlier earned ₹29.0 Cr. The Sep 2026 quarter's profit is 16.9% of that quarter's revenue. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹135 Cr (+50.0% on the year before). Why profit moved: revenue changed +28.3% on a year earlier and the margin moved +8.3 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +53.1% and revenue +25.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Bliss GVS Pharma make, and is it growing? Bliss GVS Pharma Ltd reported ₹313 Cr of revenue in the Sep 2026 quarter, +28.3% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 5.4% a year on average. The last full year, FY26, came in at ₹927 Cr. The last four reported quarters add to ₹1,074 Cr. FY26 revenue was ₹927 Cr, +14.4% on the year before. Recent pace: the last four quarters grew +25.0% on average, against 5.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +25.0%, against +15.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +43.1%, against +51.8% a year (rolling over). ## How much of every ₹100 of sales does Bliss GVS Pharma keep? Bliss GVS Pharma Ltd's operating margin was 25.9% in the Sep 2026 quarter, 8.3 percentage points higher than the same quarter a year ago. Across 13 years it has been between 15.6% and 28.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +7.9 percentage points on the year while gross margin changed +10.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Bliss GVS Pharma's profit turning into cash? Over the last 3 years, 113% of Bliss GVS Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹139 Cr of operating cash against ₹135 Cr of profit. After ₹57.0 Cr of spending on assets, ₹82.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 113% of profit came in as cash: the cash cycle got 77 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 1.8× depreciation over three years. The next section checks what that spending is building. ## Where does Bliss GVS Pharma's cash go? Bliss GVS Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 244 days in FY26, down from 321 days in FY21. It spent ₹161 Cr on assets over the last 3 years. Customers take 204 days to pay, and stock sits for 129 days on average. At FY26 sales of ₹927 Cr, each day of that cycle ties up about ₹2.5 Cr, so roughly ₹620 Cr is tied up in the business at any time. FY26: customers took 204 days to pay and stock sat for 129 days, about 4.2 months of sales sitting as stock, for a full cycle of 244 days, shorter than FY21's 321. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 129 days. Customers pay about 204 days after that. Suppliers are paid at 89 days. Together that makes the 244-day cycle. Spending on assets: ₹161 Cr over the last 3 years, against ₹88.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹6.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Bliss GVS Pharma's P/E ratio, and how does it compare with its own history? Bliss GVS Pharma Ltd's P/E is 44.8×, about the highest it has ever been. Its usual P/E (the middle reading) is 16.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +52.6% while the price moved +325.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +46.5% a year; about +15.4% a year came from earnings growth and about +31.1 percentage points from the multiple (the market paying more); over 10 years the price moved +18.1% a year; about +6.9% a year came from earnings growth and about +11.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 73% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Bliss GVS Pharma business getting better or worse? Bliss GVS Pharma Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +61.1% at its peak to +43.1%, but the business is still expanding, with ROCE rising at 17.0% (four quarters to FY26). This is based on 10 quarters of 4 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Bliss GVS Pharma earn on its capital? Bliss GVS Pharma Ltd earned a ROCE of 17% in FY26. That is up from a low of 12% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 14.6% net margin and 0.62× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 14.6% net margin × 0.62× asset turnover × 1.25× leverage (assets divided by equity) ≈ 11.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 73% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Bliss GVS Pharma have too much debt? Bliss GVS Pharma Ltd had ₹22.0 Cr of borrowings against ₹1,193 Cr of equity in FY26, so its debt is 0.02× its equity. Its operating profit is 14 times its interest bill. Over 5 years borrowings went from ₹122 Cr to ₹22.0 Cr. Over the last 3 of those years it spent ₹161 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 73% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Bliss GVS Pharma shareholding pattern? Promoters raised their stake in Bliss GVS Pharma Ltd by 15.3 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 50.1% of the company. Foreign institutions moved −7.1 points over the same period, to 5.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +15.3 points over 8 quarters, to 50.1%; Foreign institutions: −7.1 points over 8 quarters, to 5.0%; Domestic institutions: +3.1 points over 8 quarters, to 9.6%. Why the owners changed: foreign institutions moved −7.1 points and domestic institutions +3.1 points over 8 quarters, while promoters moved +15.3 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Bliss GVS Pharma from balance-sheet trouble? For Bliss GVS Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Bliss GVS Pharma rank in its industry? 65.3 out of 100, rank 8 of 44 in Pharma - Formulators, with 82% of the evidence available. Bliss GVS Pharma Ltd scores 65.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 8. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 30.2 + 14.5 + 6.5 + 14.1 = 65.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bliss GVS Pharma compared with? Bliss GVS Pharma ranks 8 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 65.3 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. Bliss GVS Pharma Ltd this page BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Bliss GVS Pharma in size? Bliss GVS Pharma is the 27th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Akums Drugs & Pharmaceuticals, Strides Pharma Science and Suven Life Sciences. Just below it: FDC, Kwality Pharmaceuticals and Gufic BioSciences. ### Pharma - Formulators companies close in size 1. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) ₹11,272 crore 2. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) ₹8,832 crore 3. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) ₹7,507 crore 4. Bliss GVS Pharma Ltd ₹7,238 crore 5. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) ₹6,087 crore 6. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) ₹4,366 crore 7. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) ₹4,235 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [ISGEC Heavy Engineering Ltd](https://www.sectoralpha.in/stocks/isgec-heavy-engineering-ltd) ₹7,280 crore · Infra - Engineering - General 2. [Tata Teleservices (Maharashtra) Ltd](https://www.sectoralpha.in/stocks/tata-teleservices-maharashtraltd) ₹7,245 crore · Telecom Services 3. Bliss GVS Pharma Ltd ₹7,238 crore 4. [Mishra Dhatu Nigam Ltd](https://www.sectoralpha.in/stocks/mishra-dhatu-nigam-ltd) ₹7,226 crore · Aerospace & Defence - Equipments 5. [Kama Holdings Ltd](https://www.sectoralpha.in/stocks/kama-holdings-ltd) ₹7,224 crore · Finance - Holding Company ## What else do people ask about Bliss GVS Pharma? ### What is Bliss GVS Pharma's share price today? Bliss GVS Pharma Ltd's share price is ₹680.35, +325.8% over the past year. The whole company is worth ₹7,239 Cr on the market. In the last 52 weeks it traded between ₹144 to ₹740; today it is 90% of the way up from the low, 43.8% above its 200-day average (as of 18 November 2026). ### What were Bliss GVS Pharma's latest quarterly results? Bliss GVS Pharma Ltd reported revenue of ₹313 Cr and net profit of ₹53.0 Cr for the Sep 2026 quarter. Revenue rose 28.3% and profit rose 82.8% compared with a year earlier. Earnings per share were ₹4.91. The operating margin was 25.9%, 8.3 percentage points higher than a year earlier (as of 18 November 2026). ### What is Bliss GVS Pharma's market cap? Bliss GVS Pharma Ltd's market capitalisation is ₹7,239 Cr at a share price of ₹680.35. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Bliss GVS Pharma performing? Bliss GVS Pharma Ltd's share price has been rising for 72 weeks. In its latest quarter, revenue rose 28.3% and profit rose 82.8% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 18 November 2026). ### Will Bliss GVS Pharma's share price go up? This page does not forecast Bliss GVS Pharma Ltd's share price. What it shows instead: the share price is ₹680.35, and it has been rising for 72 weeks. Its P/E of 44.8× is higher than 98% of its own last 11 years (as of 18 November 2026). ### Who owns Bliss GVS Pharma? Promoters own 50.1% of Bliss GVS Pharma Ltd, foreign institutions 5.0%, domestic institutions 9.6% and the public 35.3% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 15.3 percentage points over 8 quarters (as of 18 November 2026). ### Where is Bliss GVS Pharma in its business cycle? Bliss GVS Pharma Ltd's FY26 operating margin was 18.1%, against a 13-year range of 15.6% to 28.5%. The latest quarter was 25.9%, near the top of its own range. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Bliss GVS Pharma story? The main question: the share price moved +325.8% in a year while yearly earnings per share moved +52.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Bliss GVS Pharma a stock worth studying right now? What the numbers show: Bliss GVS Pharma Ltd's share price has risen faster than its earnings: +325.8% in a year, against +52.6% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ## Lists - Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.